Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER negative, HER2-negative, PR negative status confers therapeutic sensitivity to Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab 200mg in combination with carboplatin (AUC 5) and weekly paclitaxel 80mg/m^2 followed by doxorubicin and cyclophosphamide (AC 60/600) for reimbursement as a treatment option for the neoadjuvant treatment, and then pembrolizumab as a monotherapy treatment as an adjuvant treatment after surgery, of locally advanced or early stage triple negative breast cancer at high risk of recurrence in adult patients.
This statement is based on a regulatory approval from the Health Service Executive:
Pembrolizumab in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.